OBE/EPO‐INT‐03.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 72, multiple myeloma; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 12‐13 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: Hb change; secondary: QoL, Hb response, transfusion, safety
Notes	study number = 92503
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization